Search

US-20260124176-A1 - INHIBITOR FOR RETINOCHOROIDAL DISORDERS

US20260124176A1US 20260124176 A1US20260124176 A1US 20260124176A1US-20260124176-A1

Abstract

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

Inventors

  • Kazuhiro Kimura

Assignees

  • YAMAGUCHI UNIVERSITY

Dates

Publication Date
20260507
Application Date
20250612
Priority Date
20130522

Claims (14)

  1. 1 . A method of inhibiting or reducing scar formation in the retina and/or choroid of a subject in need thereof, said method comprising: (a) providing a subject scheduled for an ocular surgery, and (b) administering to said subject palovarotene ((E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid), or a salt thereof, in an amount effective to inhibit or reduce the scar formation.
  2. 2 . The method of claim 1 , wherein the administering comprises administering by instillation.
  3. 3 . The method of claim 1 , wherein said palovarotene is in the in the form of a suspension, emulsion, or instillation.
  4. 4 . The method of claim 3 , wherein the instillation comprises a solubilizer.
  5. 5 . The method of claim 4 , wherein the solubilizer is selected from the group consisting of polysorbate 80, polyoxylethylene hydrogenated castor oil 60, and macrogol 4000.
  6. 6 . The method of claim 5 , wherein the solubilizer is polysorbate 80.
  7. 7 . The method of claim 3 , wherein the concentration of said palovarotene in the instillation is 0.05% (W/V), 0.3% (W/V), 0.5% (W/V), or 1% (W/V).
  8. 8 . The method of claim 1 , wherein said palovarotene is in the form of liquid formulation.
  9. 9 . The method of claim 8 , wherein the concentration of said palovarotene in the liquid formulation is from 0.000001% to 10% (w/v), from 0.00001% to 3% (w/v), or from 0.0001% to 1% (w/v).
  10. 10 . The method of claim 8 , wherein the concentration of said palovarotene in the liquid formulation is 0.05% (w/v), 0.3% (w/v), 0.5% (w/v), or 1% (w/v).
  11. 11 . The method of claim 8 , wherein the liquid formulation comprises a solubilizer.
  12. 12 . The method of claim 11 , wherein the solubilizer is selected from the group consisting of polysorbate 80, polyoxyethylene hydrogenated castor oil 60, and macrogol 4000.
  13. 13 . The method of claim 12 , wherein the solubilizer is polysorbate 80.
  14. 14 . The method of claim 1 , wherein said palovarotene is administered to said subject in one or more daily doses.

Description

The present invention relates to an inhibitor of retinochoroidal disorder comprising (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt thereof as an effective ingredient. BACKGROUND ART In Japan where the society has an aging population, the ratio of vitreoretinal diseases such as diabetic retinopathy, retinal detachment, and age-related macular degeneration is expected to continue to increase as a cause of blindness. Prognosis of such diseases, which resulted in blindness in the past, is improving by the development of vitreoretinal operation and introduction of biopharmaceuticals, such as anti-VERF intraocular injections. However, aside from initial symptoms, the prognosis of visual functions in severe cases, where symptoms were left untreated for a long period of time or are recurring, is still not favorable. Even if retinopexy is attained by an operation or intraocular neovascularity can be devised to disappear with a pharmaceutical agent, photoreceptor functions would decrease if retinal cells have already suffered an irreversible secondary damage. Eyes are organs, for which healing of injury would be completely meaningless if photoreceptor functions are lost. Thus, in order to maintain normal retinal functions, it is important how an ophthalmic inflammation and the following secondary reaction can be controlled with the least amount of damage. Along with the calming or progression of an ophthalmic inflammation, a retinochoroidal fibrotic scar is often formed in epiretinal, intraretinal, or subretinal tissue and in some cases leads to a disorder in photoreceptor cell functions. Collagen, which is one of the components of the stroma and retinal pigment epithelial cells, particularly type I collagen, is known as a representative cell component constituting a retinochoroidal fibrotic scar. Retinochoroidal dysfunction occurs due to the formation and atrophy of a retinochoroidal fibrotic scar. In this regard, it is considered effective against retinochoroidal disorders to inhibit atrophy of collagen, particularly type I collagen, of retinal pigment epithelial cells or the like to prevent deformation or disintegration of a tissue structure. To date, a medicament for the prevention and/or treatment of diabetic retinopathy or age-related macular degeneration having an agonist of a retinoic acid receptor (hereinafter, also referred to as “RAR”), all-trans retinoic acid or 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid, as an effective ingredient (for example, see Patent Literature 1). However, since such an effective ingredient does not have selectivity with respect to RAR subtypes RARα and RARβ, the contribution of each RAR subtype to improvement in the retinal function is unknown. Meanwhile, RAR is involved in various effects such as growth, morphogenesis, and differentiation in many cells such as inflammatory cells, immune cells, and structural cells. Further, it is verified that there is a difference in the distribution of RAR subtypes depending on the tissue or organ of a mammal. Some of the effects of RAR are undesirable, such as increase in triglyceride due to RARα. Thus, the specificity or selectivity with respect to subtypes in compounds with RAR agonist activity is expected to lead to reduction in risk of side effects. For the above reasons, there is a demand for RAR agonists, which have a strong effect of inhibiting retinochoroidal disorders and are highly safe based on subtype selectivity. (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid is disclosed to be useful as a RARγ selective agonist against pulmonary emphysema, cancer, and dermatosis (for example, see Patent Literature 2) and against neurological pain (for example, see Patent Literature 3). However, there is no study that has examined the pharmacological effect of (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof, or a salt thereof on retinochoroidal disorders, particularly the formation and atrophy of a retinochoroidal scar, or a document suggesting such an effect. [PTL 1] Domestic Publication of PCT International Publication No. 2007/037188[PTL 2] International Publication No. WO 2002/028810 pamphlet[PTL 3] International Publication No. WO 2008/057930 pamphlet SUMMARY OF INVENTION The objective of the present invention is to provide an inhibitor for a retinochoroidal disorder, particularly an inhibitor for the formation and atrophy of a retinochoroidal scar in epiretinal, intraretinal, or subretinal tissue. The search for a drug that is effective against ophthalmic diseases, particularly retinochoroidal disorders in vitreoretinal diseases, is an objective that is important and of interest in the field of ophthalmology. After diligent research to find a drug that is effective